| Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers. | |
| | |
MedLine Citation:
|
PMID: 22298734 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Potential interactions between the imidazopyridine anxiolytic alpidem and the full benzodiazepine agonist lorazepam were assessed in a randomized, double-blind, four-way cross-over, placebo-controlled study in 16 healthy young male volunteers. Each volunteer received alpidem, 50 mg, or a placebo twice daily for 8 days with a 1- week wash-out interval. The interaction between alpidem, at the steady state, and a single oral dose of lorazepam 2 mg or a placebo was assessed after concomitant administration on days 7 or 9 of each treatment period. Psycho motor performance and cognitive function were evaluated before and 2, 4, 6 and 8 h post-dose, using objective tests [critical flicker fusion threshold (CFF), choice reaction time (CRT), digit-symbol substitution (DSST), body sway and short-term memory (Sternberg memory scanning)] and self-ratings [line analogue rating scales: (LARS)]. Long-term memory (delayed free recall and recognition of pictures) was assessed before the dose and 2 and 4 h post-dose. Pharmacodynamic interactions were evaluated by applying repeated measures ANOVA to a 2 x 2 factorial interaction model. Alpidem, 50 mg twice daily at the steady state, was free of any clinically relevant detrimental effects on skilled performance, information processing or memory. In contrast, a single 2 mg dose of lorazepam induced marked impairment of psychomotor performance and cognitive function (significant reductions in CFF and DSST and increases in CRT and body sway), as well as subjective sedation from 2 to 8 h post-dose, depending on the test used. In addition, lorazepam induced anterograde amnesia, characterized by a decrease in delayed free recall and recognition, and a deficit in short-term memory. Finally, alpidem 50 mg did not potentiate the detrimental effects of lorazepam 2 mg. On the contrary, alpidem significantly antagonized the lorazepam-induced CRT increase and anterograde amnesia, and produced similar trends on most of the other cognitive parameters; thus, the results obtained with the combination of alpidem and lorazepam consistently indicated less impairment than those measured after lorazepam alone. These results are consistent with the suggested partial agonsist properties of alpidem at the benzodiazepine receptor and indicate that such properties can be assessed in humans based on antagonism of the effects of a full agonist. |
| | |
Authors:
|
A Patat; M C Perault; B Vandel; P Danjou; S Brohier; I Zieleniuk; P Rosenzweig |
Related Documents
:
|
22783044 - Mangiferin, a natural xanthone, accelerates gastrointestinal transit in mice involving ... 7521474 - Effect of various angiotensin receptor antagonists on cardiovascular responses to angio... 872494 - Linear dose response and quantitative attenuation by potassium of the inotropic action ... 9024174 - Dup 532, an angiotensin ii receptor antagonist: first administration and comparison wit... 6146424 - Alfentanil kinetics in the elderly. 11381184 - Effect of high-dose progestogen on hemostatic properties of blood in patients with endo... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of psychopharmacology (Oxford, England) Volume: 9 ISSN: 0269-8811 ISO Abbreviation: J. Psychopharmacol. (Oxford) Publication Date: 1995 Jan |
Date Detail:
|
Created Date: 2012-02-02 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8907828 Medline TA: J Psychopharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 91-101 Citation Subset: - |
Affiliation:
|
Synthélabo Recherche, Clinical Research Department, Clinical Pharmacology Section, 31, Av. Paul Vaillant Couturier, B. P. 110, 92225 Bagneux Cedex. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A cognitive dysfunction in anxiety and its amelioration by effective treatment with SSRIs.
Next Document: An assessment of resedation following flumazenil-induced antagonism of intravenous midazolam: compar...